{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-034688","form_type":"8-K","ticker":"BOLT","cik":"0001641281","company_name":"Bolt Biotherapeutics, Inc.","filed_at":"2024-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.945274+00:00","generated_at":"2026-06-04T09:54:46.388132+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Bolt Biotherapeutics reports Q4/FY2023 results; cash $128.6M funds through late 2025","bullets":["Cash, cash equivalents, and marketable securities at $128.6M as of Dec 31, 2023; expected to fund through late 2025.","Collaboration revenue $2.1M in Q4 and $7.9M for FY2023, up from $1.4M and $5.7M prior year.","Loss from operations improved to $19.8M (Q4) and $76.2M (FY2023) vs $21.0M and $90.3M.","BDC-1001 Phase 2 advancing in five HER2-positive tumor cohorts; 29% ORR at RP2D reported at ESMO 2023.","BDC-3042 Phase 1 cleared three dose levels without DLT; now enrolling fourth cohort."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-034688","json":"https://secwatch.observer/filing/0000950170-24-034688.json","markdown":"https://secwatch.observer/filing/0000950170-24-034688.md","text":"https://secwatch.observer/filing/0000950170-24-034688.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641281/000095017024034688/0000950170-24-034688-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641281/000095017024034688/bolt-20240321.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T09:54:46.388132+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b29fc505449c65fd5cc48ce32dc84f7adacfb414","claim":"Bolt Biotherapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.","evidence_excerpt":"On March 21, 2024, Bolt Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641281/000095017024034688/0000950170-24-034688-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}